Biogen Inc (BIIB)
Biogen Inc. is a biotechnology company whose common stock is listed on NASDAQ under the symbol BIIB. The company discovers, develops, manufactures, and delivers therapies for patients in the United States, Europe, Germany, Asia, and other international markets. Its portfolio includes treatments for multiple sclerosis, spinal muscular atrophy, Friedreich’s ataxia, amyotrophic lateral sclerosis, plaque psoriasis, Alzheimer’s disease, postpartum depression, and several B-cell related cancers and autoimmune conditions. Biogen’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, SPINRAZA, SKYCLARYS, QALSODY, LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and other anti-CD20 therapies, along with select biosimilars. The company also maintains collaboration and licensing relationships with multiple biopharmaceutical partners, including Eisai, UCB, Genentech, Ionis, Samsung Bioepis, and Sage Therapeutics. Founded in 1978 and headquartered in Cambridge, Massachusetts, Biogen remains focused on neurological and related therapeutic areas.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BIIB
|
$267.34
|
6.6% Upside
|
Fair
|
$268.26
|
7.0% Upside
|
Fair
|
Good
|
0.0%
|
February 17, 2027
|
106.7x
|
2.0x
|
3.6x
|
37.072 B
|
43.111 B
|
17.3%
|
99.6%
|
6.2
|
595.9%
|